MAP2K7 and cancer: Since the discovery of the first ERK experimental inhibitor PD98059 20 years ago [8], new MEK inhibitors occupying highly specific allosteric sites of the target molecules have provided the opportunity to achieve higher selectivity and have also contributed to validate MEK as a cancer drug target [9].